The physical properties of I-131 may be suboptimal for the delivery of therapeutic radiation to bone marrow metastases, which are common in the natural history of neuroblastoma. In vitro and preliminary clinical studies have implied improved efficacy of I-125 relative to I-131 in certain clinical situations, although areas of uncertainty remain regarding intratumoral dosimetry. This prompted our study using human neuroblastoma multicellular spheroids as a model of metastasis. 3D dose calculations were made using voxel-based Medical Internal Radiation Dosimetry (MIRD) and dose-point-kernel (DPK) techniques. Dose distributions for I-131 and I-125 labeled mIBG were calculated for spheroids (metastases) of various sizes from 0.01 cm to 3 cm diameter, and the relative dose delivered to the tumors was compared for the same limiting dose to the bone marrow. Based on the same data, arguments were advanced based upon the principles of tumor control probability (TCP) to emphasize the potential theoretical utility of I-125 over I-131 in specific clinical situations. I-125-mIBG can deliver a higher and more uniform dose to tumors compared to I-131 mIBG without increasing the dose to the bone marrow. Depending on the tumor size and biological half-life, the relative dose to tumors of less than 1 mm diameter can increase several-fold. TCP calculations
Introduction
Neuroblastoma is a pediatric solid malignancy derived from primitive adrenergic neuroblastic tissue. A multimodality treatment approach is the current standard of care for this disease, employing combinations of surgery, radiotherapy, *Corresponding author: Dr. Wilson H. Y. Roa, M.D., M.Sc., FRCPC, ABR Phone: (780) 432-8783 E-mail: wilson.roa@albertahealthservices.ca chemotherapy and immunotherapy depending upon a particular patient's risk stratification (1). Neuroblastic tissue normally gives rise to the sympathetic nervous system (2), and neuroblastoma accumulates catecholamine selectively. This property has been exploited for therapeutic gain, as targeteted therapy with radiolabeled metaiodobenzyl-guanidine (mIBG), an analog of catecholamine, is well established in treating advanced presentations of this disease (3) (4) (5) (6) . In addition, human monolayer cultures and cell suspensions have demonstrated both cytotoxicity and altered morphology in surviving cells after treatment with radiolabeld mIBG (7-9), while animal models have documented gross reductions in tumor volumes following similar treatment (10). Radiolabeled mIBG also forms a component of combined modality immunotherapy regimens (11, 12) , and it is useful as an imaging agent for neuroblastic tumors (13).
However, neuroblastoma has a propensity for early metastasis to the bone marrow, a known dose-limiting structure for radiolabelled-mIBG therapy (14-16), and partly because of this, clinical outcomes with mIBG remain less than satisfactory (17). One strategy to address this toxicity is to alter iodine isotope to which the mIBG is conjugated. I-131 is the most commonly used isotope in clinical practice. However, several other iodine isotopes are known (47 in total), but only a handful of these have been used clinically (Table I) . Of these, I-125 is particularly attractive because of its decay scheme, which is characterized by short-range Auger electrons in addition to X-and Gamma-rays, resulting in a highly localized deposition of dose. In contrast electrons emitted from I-131 have a longer path-length, with dose deposition being more dependent upon cross-dose from activity in adjacent regions, and less upon local dose deposition. In addition, the Relative Biological Effectiveness (RBE) of Auger electrons located in close vicinity to DNA can be as great as high-LET alpha particles, causing a high frequency of double strand breaks, and potentially overcoming the deleterious effects associated with low dose-rate irradiation of cancerous/tumor cells and cellular repair (18) (19) (20) (21) .
Therefore, for the treatment of neuroblastoma metastases in the bone marrow, it is suggested that for any given activity, I-125-mIBG could be less toxic to the bone marrow overall. Furthermore, it follows that I-125-mIBG should be more effective at treating smaller accumulations of metastatic disease than I-131, given its shorter path-length and decreased reliance upon cross-dose deposition. There is certainly support in the literature for both these suppositions. In one of the few trials reporting on the clinical application of I-125-mIBG, I-131-mIBG was 2.6 times more potent than I-125-mIBG at inducing platelet declines to 10% of pretherapeutic levels, while I-125-mIBG could be given safely, with encouraging clinical benefit (22). Mathematical modeling of tumor dosimetry has suggested that long-range β-emitters provide sufficient energy deposition within the tumor for sizes 200 µm, while implying that low-range Auger emitters are appropriate for tumor sizes ,200 µm (23), with especially efficient intratumor energy deposition reported for I-125 at tumor diameters of 0.012 cm (24).
On a fundamental level, the cytotoxic efficacy of any radiolabelled compound depends upon the distribution of activity (and resultant dose) within a cell relative to the critical targets located therein. For neuroblastoma, the most critical cellular target is the nucleus (25). However, there is minimal uptake of mIBG in the nucleus itself, with most of the mIBG being taken up by the surrounding cytosol (26-28). Furthermore, there is very little clinical information available regarding the kinetics of in vivo MIBG biodistribution, uptake and accumulation following its initial intravenous administration. This is further complicated by the fact that multiple organs will take up mIBG, in addition to the intended target neuroblastoma tissue itself (29, 30) .
Overall, the optimum clinical implementation of mIBG therapy still needs to be defined (31, 32) . We hope that the framework established here will enable the relative merits of I-125 and I-131 to be compared directly in the setting of metastatic neuroblastoma, providing insight into possible future improvements in the therapeutic approach to this disease. For an activity density a(r9, t) distributed in a uniform and homogeneous medium, the dose D(r, t) at point r in continuum space and at time t is given by the DPK convolution formula,
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where K(r2r9) is the DPK function or convolution kernel for the specific isotope in the medium. A calculation method and an extensive compilation of DPKs for beta emitters has been published previously (34), while a method originally presented in MIRD Pamphlet No. 2 is used frequently for photon emitters (35).
Assuming a uniformly distributed activity a(r9, t) in source voxel h, the average dose D k in a target voxel k at time t can be written,
where Ã h is the cumulated activity given by and S k h ← is the S-factor from source voxel h to target voxel k, Finally, following MIRD formalism, the cumulated dose to the tumor was then determined from,
where A 0 and t res are respectively the initial activity and the residence time of the radiolabeled compound in the tumor volume, and S is the S-factor for the given isotope of interest calculated from Eq.
[4], with h 5 k in this case.
Dose Variation
The relative efficacy of I-125 vs. I-131 mIBG for tumor treatment was estimated by comparing the total dose delivered to the tumor by each isotope, while assuming the same limiting dose to the bone marrow. Bulk normal tissue dose estimates for these radiopharmaceuticals are available and yield limiting red marrow doses of 1.2 3 10 22 mGy/MBq for I-125-mIBG and 7.4 3 10 22 mGy/MBq for I-131-mIBG (37). Assuming identical uniform uptake kinetics for either isotope, it follows that I-125-mIBG may be administered to a patient at an activity of 6.17 times the administered activity of I-131-mIBG without increasing radiation toxicity to the bone marrow. However, this may be weighed against the 7-8 times higher number of I-125 atoms required for achieving the same activity in the tumor simply because of its longer half-life. In this case, the relative dose to the tumor for I-125 and I-131 for equivalent bone marrow toxicity is estimated by, 
The residence time t res in tumors may not be identical for the two compounds. For simple exponential decay, the residence time is given by,
.
where T eff is an effective half-life, T p is the physical half-life (60.14 days for I-125; 8.02 days for I-131) and T b is the biological half-life of mIBG in tumor tissues. [6] was used to quantify the general effect of variable T eff , as well as the variation of dose with tumor size and spatial location within the spheroid. Bulk absorbed dose rates to tumor spheroids of 0.01 cm through 3 cm diameter were calculated assuming a uniform distribution of activity throughout each spheroid, with the inherent assumption of equal toxicity to bone marrow with either isotope as described above.
Tumor Control Probability Estimation
The relative efficacy of I-125 versus I-131 was also addressed via tumor control probability (TCP) modeling. This approach enabled direct comparison of the two isotopes in terms of activity, tumor size and resultant clinical effect. We assumed an idealized case of neuroblastoma tumor spheroids, each taking up mIBG uniformly, with all activity confined to the spheroid and decaying according to first-order kinetics. TCP estimates were derived using the following TCP model for a spherical tumor (39):
Here, V t represents the total volume of the sphere, subdivided into M concentric shells; r j is the radius of each shell; f rj is the total volume of each shell as a fraction of V t ; D rj is the total dose deposited within each shell; the clonogenic cell density within each shell is given by r rj .
A number of assumptions were made to adapt this model for use here. The original form of this model assumed fractionated radiotherapy at a standard 2 Gy fraction size, not the extended, continuous dosing due to first-order decay which would occur in actual practice. In addition, only the radiobiological a parameter (a i ) was included (with the contribution of the b parameter assumed negligible in the setting of 2 Gy fractions).
Finally, despite dosing occurring over a protracted period of time, cellular repair was not overtly included. However, at the activities considered in our calculations, the dose would be continuous, so there would presumably be insufficient cellular repair. In addition, the density of double strand breaks associated with the release of I-125 Auger electrons from the selective DNA-bound I-125 could further overwhelm the cellular repair processes (40). Therefore, despite these assumptions and modifications, this TCP model was felt to be a reasonable vehicle for illustration of the principles put forward here.
Because we assumed a uniform distribution of tracer in a spheroid, the total dose (D rj ) at any constant radius in the spheroid would be identical. For our shell-based model, it was assumed that S would also be the same throughout each shell, with the local dose therein defined according to Eq. [5]. To calculate dose, we used a random number generator together with published values (41) of the mean and standard deviation of α for human neuroblastoma cells (0.54 Gy 21 and 0.249 Gy 21 , respectively) to generate a set of K normally distributed values of a i . Similarly, we used published values of 37.0 h and 16.5 h for the mean and standard deviation of T eff for I-131-mIBG in humans to generate a set of L normally . For clonogenic cell density r rj , we assumed a typical value of 10 9 cells/cm 3 .
To account for the locally reduced dose to the nucleus, we adapted our MIRD model by reducing the calculation volume to that of a single cell. The distribution of dose within this single cell was calculated for 2 cases: (1) zero uptake in the nucleus with uniform uptake in the remaining cytosol;
(2) uniform uptake in the nucleus and cytosol. For an assumed standard neuroblastoma cell size of 25 μm (the cell size approximates two to three red blood cell diameters) (43), and assuming a nuclear-cytoplasmic ratio of 50%, we generated local dose-reduction factors (d) for each isotope, representing the ratio of dose to the nucleus for case (1) to that of case (2). The dose-reduction factors were then applied for the purposes of TCP dose calculation to reduce the dose within every shell as a reasonable attempt to account for the dichotomous distribution of activity within each cell.
The final adjusted TCP equation took the following form:
This equation was translated into computer code, enabling TCP to be calculated for any desired combination of isotope, tumor size, administered activity, cellular density and residence time for the known distributions of S-factors. Nine separate spherical tumor spheroid diameters were examined, 0.01 cm, 0.02 cm, 0.05 cm, 0.10 cm, 0.20 cm, 0.50 cm, 1.0 cm, 2.0 cm and 3.0 cm. We generated 250 values of a and 250 values of T res at each activity, representing 62500 separate TCP calculations at each activity. We generated curves of TCP versus activity over a broad range of activities, for each of the nine spheroid diameters. Regardless of the isotope, the ordinate for these TCP curves was the administered activity of I-131, reflecting our underlying assumption that dosing by either isotope would be limited only by equivalent bone marrow toxicity as defined in Eq. [6]. The mean TCP and sample standard deviation were also calculated at every activity, to quantify the local variation of TCP with activity further, and to facilitate an assessment of statistical significance for any observed TCP differences.
Results

Dose Estimation
The calculated average individual absorbed dose factors (mGy/MBq-s) are presented in Table II , with the individual contributions from Auger and conversion electrons (CE), beta, X-ray and gamma radiation specified for each isotope. Figure 1 shows the calculated ratio D I-125 /D I-131 determined from Eq.
[6] and Table II , incorporating the influence of biological half-life in addition to tumor diameter. This figure shows that as the biological half-life in the tumor tissue increases, I-125-mIBG becomes increasingly advantageous over I-131-mIBG in terms of the delivered dose to the tumor spheroid. This figure also illustrates that the increased dose associated with I-125 is comparatively larger for the smallest diameter spheroids, trailing off for larger spheroid diameters. Figure 2 shows the local radial variation of the calculated S-factors for each isotope, normalized to the S-value at the origin (x 5 0), for a range of spheroid diameters. For the smallest diameters, it is immediately apparent that I-125-mIBG provides a more homogeneous distribution of dose than I-131-mIBG, given the much more rapid fall-off of dose (or rather S-factor) at the spheroid edge that is seen. However, for the larger diameters, the dose from I-131-mIBG becomes much more homogeneous in the vicinity of the spheroid edge, even more so than that seen for I-125-mIBG.
The calculated S-factors are presented slightly differently in Figure 3 , where the raw (i.e. non-normalized) S-factors are presented, this time relative to a normalized radial distance from the origin. These curves more or less support the same arguments regarding dose (S) homogeneity at the spheroid edge that were illustrated by Figure 2 . It is interesting that for a given spheroid diameter, the S-factors calculated for I-131-mIBG are consistently larger than those calculated for I-125-mIBG, though the magnitude of this difference is small at the The local variation of dose ratio (D 125 /D 131 ) presented in Eq.
[6] was calculated for the entire set of radially varying S-factors, assuming again equivalent toxicity to bone marrow with either isotope. The results are presented in Figure 4 . The radial distance was normalized to the total spheroid radius, so that all spheroids could be compared directly. The curves shown represent only the case of T b 5 44.5 h. As with Figure 1 , these curves would also vary with T res , such that any positional shift of these curves due to T b would be of the same order of magnitude as that shown in Figure 1 . This figure illustrates several important points. Firstly, for the smallest spheroid diameters (i.e. those  0.05 cm), it appears advantageous to use I-125-mIBG instead of I-131-mIBG given that the calculated dose-ratio is .1. For the largest spheroids shown, the dose ratio is ,1, implying that I-131-mIBG would be more effective in terms of dose deposition. The second important point illustrated by this figure is that regardless of spheroid diameter, the dose delivered to the spheroid edge is substantially greater with I-125-mIBG relative to I-131-mIBG. In other words, I-125-mIBG produces generally homogeneous dosedeposition at the spheroid edge, delivered with a simultaneous "boost" to this same region. Such a boost would certainly be desirable, especially given that the most actively proliferating portion of the tumor would tend to be at the peripheral rim. As with Figures 2 and 3 , these curves represent a T b 5 44.5 h, with an accentuation of the dosimetric characteristics favoring I-125-mIBG as the T res is increased.
Tumor Control Probability Analysis
The results of the dose-reduction analysis (i.e. to define the necessary values of d for TCP modeling given the limited Figure 2 : Radial dose profiles for various tumor diameters for I-125-mIBG versus I-131-mIBG. The I-125-labeled mIBG delivers a more uniform and higher dose to the tumoral tissue for the smallest spheroid diameters, while this difference becomes less apparent for larger spheroid diameters. The dose to the tumor is normalized to yield the same dose to the bone marrow, which is the limiting factor for this therapy.
Figure 3:
Variation of S-factor with normalized spheroid diameter for I-125 and I-131. In general, the dose from I-125 is much more uniformly distributed at the spheroid margin than the dose from I-131. This difference is most prominent for the smallest spheroid diameters, where the S-values for I-131-mIBG decline relatively slowly past the spheroid limit. For higher spheroid diameters, either isotope produces reasonably uniform coverage. Quantitatively, the S-values are greatest for the smallest spheroid diameters, with S for I-131 being greater than those for I-125 (with this difference also disappearing for the smallest diameters).
Figure 4:
Radial variation of Dose-ratio (for same limiting toxicity to bone marrow). The dose-ratio presented in Eq.
[6] is plotted for a variety of spheroid diameters. Again, we assumed equal toxicty to bone marrow, such that I-125 could be given at an activity 6.17 that of I-131. For spheroid diameters ,0.05 cm, the dose delivered by I-125 was consistently higher than that delivered by I-131. This difference was prominent at the spheroid rim, where I-125 appeared to be especially advantageous. For spheroid diameters .0.1 cm, it appears that I-131 would be more advantageous dosimetrically. These curves emphasize the dosimetric differences between the two isotopes, implying a potential for mixed-isotope therapy, whereby some combination of I-125 and I-131 would be used, enabling the favorable properties of each isotope to be exploited for potential therapeutic gain. uptake into the nucleus) are presented in Figure 5 . Separate curves are presented for each isotope. The raw (i.e., not normalized) S-factors are plotted on the left ordinate, while the normalized (i.e., all S-values divided by the S-value at the origin) S-values are plotted on the right ordinate. These figures illustrate several important points. Firstly, when nuclear uptake is not allowed, there is (not surprisingly) a clear decrease of dose to the nucleus. The magnitude of this decrease was different for each isotope however, with the nuclear dose decreasing to approximately 0.70 of that in the cytoplasm with I-131, while I-125 was associated with a decreased nuclear dose to approximately 0.300 of that in the cytoplasm. Regardless of isotope, once the edge of the nucleus is reached, and for all points beyond, there is little difference between the local S-factors for I-125-mIBG and I-131-mIBG. Finally, the superior homogeneity of I-125-mIBG at the spheroid edge is again evident here. Based upon these results, we assumed values of d 5 0.3 for I-125-mIBG and d 5 0.7 for I-131-mIBG for insertion into Eq. [9] .
Results of our TCP analysis are presented for the case of 0.01 cm, 0.1 cm and 1 cm spheroid diameters in Figure 6 . TCP calculations were performed for all nine spheroid diameters, but only these diameters are shown here. Again, we assumed equivalent bone marrow toxicity from each isotope, all TCP results are expressed in terms of an equivalent activity of I-131-mIBG yielding equivalent marrow toxicity. Several important observations may be made from these curves. Firstly (and not surprisingly), increased activity is required to control larger tumor deposits, given the shift of these curves to the right (i.e. to higher activities) as spheroid diameter is increased. Secondly, the calculated TCP for I-131-mIBG is consistently higher that for I-125-mIBG for largest spheroid diameters. However, the magnitude of this difference decreases as the spheroid diameter is decreased, such that the calculated TCP for I-125 exceeds that calculated for I-131-mIBG for a spheroid diameter of 0.01 cm, implying that I-125-mIBG would be a more appropriate choice of isotope for spheroids of this size. This is further illustrated in Figure 7 , which shows the predicted improvement in TCP when I-125-mIBG is used. For spheroid diameters from 3 cm down to 0.1 cm, I-131-mIBG Figure 5 : Analysis for the effect of minimal nuclear uptake. Chart (A) represents the local dosimetry within a single cell that has taken up I-125-mIBG uniformly. The grey curves represent the case of uniform nuclear uptake (solid line) and zero nuclear uptake (broken line). The black curve represents the ratio of local dose for the zero-uptake case to the local dose for the uniform uptake case. The dose to the nucleus for zero nuclear uptake is roughly 0.300 that for uniform uptake, so a value of d 5 0.300 was chosen for TCP calculations. Chart (B) represents the analogous case for I-131-mIBG. A value of d 5 0.700 was chosen for TCP calculations. d for I-131 is higher than d for I-125 because of the longer path lengths and more energetic decay products associated with I-131. Of note, for either isotope, the ratio of local dose is essentially unity outside the nucleus. The dose to the tumor is normalized to yield the same dose to the bone marrow, which is the limiting factor for this therapy.
Figure 6:
Variation of TCP with spheroid diameter. Regardless of activity, the calculated TCP for I-131-mIBG is consistently higher than that calculated for I-125-mIBG at the largest spheroid diameters. However, for spheroid diameters approaching 0.01 cm, the calculated TCP for I-125-mIBG exceeds that for I-131-mIBG. This change supports the supposition that I-125-mIBG is potentially more effective than I-131-mIBG at "small" spheroid diameters, with I-131-mIBG being more effective at "large" spheroid diameters. The dose to the tumor is normalized to yield the same dose to the bone marrow, which is the limiting factor for this therapy. is theoretically favored. Any difference between the two isotopes seems to disappear around a spheroid diameter of 0.05 cm. For the two smallest spheroid diameters, 0.02 cm down to 0.01 cm (and by implication for spheroid diameters smaller than that), I-125-mIBG is theoretically favored. In every case, regardless of activity or spheroid diameter, the two TCP curves were within less than a single standard deviation (data not shown). It follows that there could be no statistically significant difference between the two isotopes in terms of TCP.
Discussion
There has been a growing interest in the therapeutic use of targeted therapies in the treatment of all types of cancer.
A successful systemic targeted therapy needs to fulfill many requirements, including favorable uptake kinetics, highly specific distribution, effective target dosimetry, and favorable clinical response, all with acceptable normal tissue toxicity. In other words, the agent must have a favorable therapeutic ratio, whereby the expected clinical benefit must exceed the expected potential toxicities.
Much of the recent work in the literature regarding radiolabeled mIBG has addressed efforts to increase this therapeutic ratio by a variety of means, ranging from the identification of novel targets and therapies (44) (45) (46) (47) to novel attempts to optimize the uptake kinetics (48) (49) (50) . Another crucial factor is the choice of radionuclide, since variations in the decay scheme, RBE and dose-rate can alter the cytotoxic effect significantly (51) (52) (53) . In addition to the prior understanding of radiation dosimetry in metastatic tumors (54), there have been recent papers that report on important advances in cellular and Auger dosimetries, and are particularly relevant to the present study in terms of its limitations and future improvements (55-59).
Our findings suggest that the current standard therapeutic approach with I-131-mIBG is dosimetrically inferior to I-125-mIBG in terms of both dose to the proliferating rim, as well as the spillover dose to the surrounding tissues. Of course, this observation may be influenced in vivo by nondosimetric factors such as a greater number of tumor clonogens at the rim, impaired penetration of drug molecules and the presence of hypoxic cells, but this fundamental dosimetric benefit should still exist, all other factors being equal. Our observation is also in keeping with previous models, which have predicted similar results (60), as well as by first principles, whereby the relatively long range of beta emissions of I-131 (an average mean range of 210 µm and a maximum range of 800 µm) would simply be expected to place this isotope at a disadvantage in the treatment of "small" tumors.
Admittedly, our TCP model was based upon a number of assumptions, and the TCP values that were generated were not meant to be predictive of actual response in vivo. They do however emphasize important, fundamental differences between I-125 and I-131 which can be used to guide treatment decisions. Our study was not specifically designed to compare mixed-isotope therapy to single-isotope therapy, but our results do in fact support the principle that combined therapy, with I-125-mIBG and I-131-mIBG administered together in some combination, would offer additional therapeutic benefit over either isotope alone. In other words, I-125-mIBG should be able to complement I-131-mIBG in treating neuroblastoma lesions of potentially widely varying size in vivo, because of the improved dosimetry to smaller sized tumors and the enhanced RBE from DNA-bound I-125. Our results also seem to be in accord with similar results presented in the literature (61-63). Therefore, in specific situations, I-125 may be considered as a suitable alternative to I-131 for intermediate tumor size, with less risk of pancytopenia and marrow toxicity (64). A logical and customized application of various combinations of isotope should be best strategized in light of the individual disease status.
Of course, our results presume adequate uptake into the neuroblastoma spheroids (and specifically into the individual neuroblastoma cells). Cellular accumulation of mIBG occurs both by a nonspecific passive diffusion into the cells, as well as by specific, high affinity, ATPase-dependent transporter mechanism, where the energy-dependent process is substantially more efficient than the passive process (65, 66). Cellular uptake of mIBG seems to correlate directly with both For the smallest spheroid diameters, I-131-mIBG is associated with consistently higher TCP estimates than those predicted for I-125-mIBG. However, this difference is predicted to disappear around a diameter of 0.01 cm, with I-125-mIBG appearing advantageous for spheroid diameters less than 0.02 cm. Again, dose to the tumor is normalized to yield the same dose to the bone marrow.
serum concentration (in vivo) and supernatant concentration (in vitro) (61). Uptake can be improved through the use of pre-dose unlabeled mIBG (67), while the degree of neuronal differentiation and the use of chemotherapy may also influence uptake (68). However, it is not entirely clear if adequate plasma concentration of mIBG can be attained to facilitate efficient cellular uptake in every patient, as a reliable means of whole body dosimetry for radioiodinated mIBG still needs to be established (69, 70). More specifically, there is substantial individual variability, so every patient must be considered individually (71).
In a recent publication, total body dosimetry for I-131 correlated directly with the administered activity per kilogram body weight, which itself correlated to significant reductions in both platelet and neutrophil counts in vivo (72). Substantially greater hematologic toxicity (i.e., requiring stem cell support) was observed at administered activity levels per kilogram of .555 MBq/kg. According to Eq.
[6], this would correspond to a total body dose of I-125 of over 3300 MBq/kg, which would correspond roughly to the range of activities examined in our illustrative TCP analysis, assuming a typical patient body weight. Considering I-125 itself, the same relationship between hematologic toxicity and dose per unit body weight was apparent in the work of Sisson and colleagues, one of the few clinical studies addressing I-125-mIBG in clinical practice (73). We reworked their published toxicity data to compare platelet toxicity and administered activity per kilogram, using linear regression. The results of this analysis are presented in Figure 8 , which demonstrates at least a weak correlation between increased platelet toxicity and increased specific activity in vivo.
In the present study we used human neuroblastoma multicellular spheroids as a three-dimensional model of metastasis to calculate radiation dosimetry for I-125-and I-131-radiolabeled mIBG. Radiation dose estimates were determined using well developed dosimetric methods based on the homogeneous distribution of mIBG as previously reported in the same model (74). Total-dose-based tumor control probability (TCP) calculations were also advanced, illustrating the manner in which tumor size, administered activity and decay properties of the isotopes correlate with potential therapeutic effect. How exactly I-125-mIBG and I-131-mIBG could be combined in the treatment of such patients, however, remains a matter for further research. These two isotopes are clearly different, and the arguments put forth in this study imply a definite role for combinations of isotopes in the treatment of this disease. It is hoped that this study will be instrumental in guiding future clinical implementation of mIBG conjugated to alternative and theoretically advantageous isotopes. 
